Global Medullary Thyroid Cancer Market

Global Medullary Thyroid Cancer Market Size Insights Forecasts to 2035

• The Global Medullary Thyroid Cancer Market Size Was valued at USD 141.3 Million in 2024
• The Global Medullary Thyroid Cancer Market Size is Expected to Grow at a CAGR of around 9.99% from 2025 to 2035
• The Worldwide Medullary Thyroid Cancer Market Size is Expected to Reach USD 402.8 Million by 2035
• Asia-Pacific is expected to grow the fastest during the forecast period.

According to a research report published by Decisions Advisors and Consulting, The Global Medullary Thyroid Cancer Market Size Was Worth Around USD 141.3 Million In 2024 And Is Predicted To Grow To Around USD 402.8 Million By 2035 With A Compound Annual Growth Rate (CAGR) Of 9.99% From 2025 To 2035. The global medullary thyroid cancer market will create future opportunities through targeted therapies, precision medicine, RET inhibitors, biomarker-based diagnosis, expanding clinical trials, emerging market penetration, combination treatments, improved genetic screening, and strategic pharmaceutical collaborations.

 

Market Overview

The global medullary thyroid cancer market refers to the worldwide industry which develops diagnostic methods and treatment solutions for medullary thyroid cancer through its targeted therapies and chemotherapy approaches and genetic testing services and associated medical services. Additionally, the current medical development of Peptide Receptor Radionuclide Therapy for Metastatic Cases has become an essential treatment option which enables doctors to treat patients who do not respond to standard tyrosine kinase inhibitors. The treatment uses medullary thyroid carcinoma cells which have high levels of somatostatin receptors to deliver specific radiation treatment that reduces overall body damage. The industry develops this new method through major investment resources which support the quick development of clinical research programs. The company obtained an equity investment of €188 million to develop its radiopharmaceutical candidates according to the press release 'ITM Raises €188m to Enhance Radiopharmaceutical Pipeline and to Strengthen Leading Position in Medical Radioisotope Manufacturing' which was published on June 2024 by ITM Isotope Technologies Munich SE.

 

Report Coverage

This research report categorizes the medullary thyroid cancer market based on various segments and regions, forecasts revenue growth, and analyzes trends in each submarket. The report analyses the key growth drivers, opportunities, and challenges influencing the medullary thyroid cancer market. Recent market developments and competitive strategies such as expansion, type launch, development, partnership, merger, and acquisition, have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key market players and analyses their core competencies in each sub-segment of the medullary thyroid cancer market. 

 

Driving Factors

The global medullary thyroid cancer market experiences its main growth driver through the development and approval of Targeted Therapeutapeutics which create major changes in treatment methods by shifting from palliative treatment to precise cancer treatment. The market currently evolves through the commercial introduction of tyrosine kinase inhibitors which target specific RET proto-oncogene mutations that cause most medullary thyroid carcinoma cases. The market transition to targeted treatment approaches receives backing from approved orphan drugs which maintain consistent revenue streams. Exelixis reported that its dedicated medullary thyroid cancer treatment Cometriq generated $11.2 million in U.S. net product revenues during the fiscal year 2024 according to the company's Fourth Quarter and Fiscal Year 2024 Financial Results which they published in February 2025. The financial outcomes of this study demonstrate that specialized treatments create market opportunities which push manufacturers to establish continuous supply chains for this specialized patient group.

 

Restraining Factors

The global medullary thyroid cancer market growth faces multiple obstacles which include high treatment costs, a small patient base, slow diagnosis times, targeted therapy side effects, strict regulatory approval requirements, insufficient awareness in developing areas and problems with reimbursement.

 

Market Segmentation

The medullary thyroid cancer market share is classified into treatment and end-user.

 

• The surgery segment dominated the market in 2024, approximately 56% and is projected to grow at a substantial CAGR during the forecast period.

Based on the treatment, the medullary thyroid cancer market is divided into surgery, radiation therapy, and chemotherapy. Among these, the surgery segment dominated the market in 2024, approximately 56% and is projected to grow at a substantial CAGR during the forecast period. The most effective first-line treatment for patients with early-stage thyroid cancer requires surgical removal of the thyroid gland through thyroidectomy. The surgical procedure generates potential for complete disease elimination while it decreases disease advancement probability according to established medical guidelines. The market segment expansion receives backing from two factors which include enhanced early detection methods and better surgical procedures.

• The electronic segment accounted for the largest share in 2024, approximately 60% and is anticipated to grow at a significant CAGR during the forecast period.

Based on the end-user, the medullary thyroid cancer market is divided into hospitals, radiation therapy center, and cancer research institutes. Among these, the hospitals segment accounted for the largest share in 2024, approximately 60% and is anticipated to grow at a significant CAGR during the forecast period.  Medullary thyroid cancer treatment needs specialized surgical methods and advanced diagnostic imaging and genetic testing and multidisciplinary medical teams which hospitals provide. Hospitals handle complex medical situations together with supervising patients after surgery and delivering specialized treatment. The segment growth is propelled by three factors which include rising patient admissions and enhanced healthcare facilities and increased expenses for cancer treatment.

 

Regional Segment Analysis of the Medullary Thyroid Cancer Market

• North America (U.S., Canada, Mexico) 
• Europe (Germany, France, U.K., Italy, Spain, Rest of Europe)
• Asia-Pacific (China, Japan, India, Rest of APAC)
• South America (Brazil and the Rest of South America) 
• The Middle East and Africa (UAE, South Africa, Rest of MEA)

 

North America is anticipated to hold the largest share of the medullary thyroid cancer market over the predicted timeframe.

North America is anticipated to hold the largest share of the medullary thyroid cancer market over the predicted timeframe. The advanced healthcare infrastructure together with high awareness levels and the strong presence of leading pharmaceutical companies and the early adoption of targeted therapies and the favorable reimbursement policies and the increasing investment in cancer research and clinical trials across the region.

 

Asia-Pacific is expected to grow at a rapid CAGR in the medullary thyroid cancer market during the forecast period. The increasing number of cancer cases together with better healthcare systems and raised public knowledge and better access to advanced medical testing equipment and higher healthcare spending and government support programs and increased pharmaceutical company investments in developing countries like China and India and Japan.

 

Competitive Analysis:

The report offers the appropriate analysis of the key organizations/companies involved within the medullary thyroid cancer market, along with a comparative evaluation primarily based on their type of offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes type development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.

 

List of Key Companies

• AstraZeneca PLC
• Sanofi AG
• Eli Lilly and Company
• Exelixis, Inc.
• F. Hoffmann-La Roche Ltd
• Novartis AG
• Merck & Co., Inc
• Bayer AG
• HUTCHMED Ltd.
• Bristol-Myers Squibb Co.
• Others

 

Key Target Audience

• Market Players
• Investors
• End-users
• Government Authorities 
• Consulting and Research Firm
• Venture capitalists
• Value-Added Resellers (VARs)

 

Recent Development

 

• In July 2025, Memorial Sloan Kettering Cancer Center reported that researchers had advanced thyroid cancer care by investigating targeted therapies such as selumetinib to restore treatment response in resistant cases, while also enhancing personalized diagnostics and clinical trials to achieve improved outcomes.

 

Market Segment

This study forecasts revenue at global, regional, and country levels from 2020 to 2035. Decisions Advisors has segmented the medullary thyroid cancer market based on the below-mentioned segments: 

 

Global Medullary Thyroid Cancer Market, By Treatment

• Surgery
• Radiation Therapy
• Chemotherapy

 

Global Medullary Thyroid Cancer Market, By End-User

• Hospitals
• Radiation Therapy Center
• Cancer Research Institutes

 

Global Medullary Thyroid Cancer Market, By Regional Analysis

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Russia
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  •  South Korea
  • Australia
  • Rest of Asia Pacific
• South America
  • Brazil
  • Argentina
  • Rest of South America
• Middle East & Africa
  • UAE
  • Saudi Arabia
  • Qatar
  • South Africa
  • Rest of the Middle East & Africa

 

Frequently Asked Questions (FAQ)

 

1. What is the projected growth of the Global Medullary Thyroid Cancer Market by 2035?

Answer: The Global Medullary Thyroid Cancer Market is projected to grow from USD 141.3 million in 2024 to USD 402.8 million by 2035, registering a CAGR of 9.99% during the forecast period 2025–2035.

 

2. Which treatment segment dominated the market in 2024 and why?

Answer: The surgery segment dominated the market in 2024 with approximately 56% share, as thyroidectomy remains the most effective first-line treatment for early-stage medullary thyroid cancer, offering potential curative outcomes.

 

3. What are the major factors driving market growth?

Answer: Key growth drivers include the development of targeted therapeutics, RET inhibitors, orphan drug approvals, precision medicine advancements, expanding clinical trials, and increasing investments in innovative treatment technologies.

 

4. Which end-user segment held the largest share in 2024?

Answer: Hospitals accounted for the largest share (around 60%) in 2024 due to availability of advanced surgical facilities, diagnostic imaging, genetic testing, and multidisciplinary cancer treatment services.

 

5. Which region leads the market and which region is growing fastest?

Answer: North America holds the largest market share due to advanced healthcare infrastructure and strong pharmaceutical presence, while Asia-Pacific is expected to grow at the fastest CAGR owing to rising cancer cases and improving healthcare investments.